The innate immune response in reperfused myocardium

Cardiovascular Research

Volumn 94, Issue 2, 2012, Pages 276-283

  Timmers, Leo ^a   Pasterkamp, Gerard ^a   De Hoog, Vince C ^a   Arslan, Fatih ^a   Appelman, Yolande ^b   De Kleijn, Dominique P V ^a,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Innate immunity; Ischaemia reperfusion injury; Myocardial infarction; Toll like receptors

Indexed keywords

C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C5; PEXELIZUMAB; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 11; TOLL LIKE RECEPTOR 12; TOLL LIKE RECEPTOR 13; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

APOPTOSIS; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; COMPLEMENT SYSTEM; CORONARY ARTERY BYPASS GRAFT; HEART INFARCTION; HEART INJURY; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE ISCHEMIA REPERFUSION INJURY; HEART MUSCLE PERFUSION; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; MESENCHYMAL STEM CELL; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

CELL-DERIVED MICROPARTICLES; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INFLAMMATION MEDIATORS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84860112830     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs018     Document Type: Review

References (95)

1. Atlas of heart disease and stroke. WHO; 2007.
2. O'Neill W, Timmis GC, Bourdillon PD, Lai P, Ganghadarhan V, Walton J Jr et al. A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. N Engl J Med 1986;314:812-818. (Pubitemid 16138680)
3. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359: 473-481.
4. Matzinger P. The danger model: a renewed sense of self. Science 2002;296:301-305. (Pubitemid 34303674)
5. Cleutjens JP, Blankesteijn WM, Daemen MJ, Smits JF. The infarcted myocardium: simply dead tissue, or a lively target for therapeutic interventions. Cardiovasc Res 1999;44:232-241. (Pubitemid 29474084)
6. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004;61:481-497. (Pubitemid 38210154)
7. Ma XL, Weyrich AS, Lefer DJ, Buerke M, Albertine KH, Kishimoto TK et al. Monoclonal antibody to L-selectin attenuates neutrophil accumulation and protects ischemic reperfused cat myocardium. Circulation 1993;88:649-658. (Pubitemid 23228066)
8. Weyrich AS, Ma XY, Lefer DJ, Albertine KH, Lefer AM. In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischemia and reperfusion injury. J Clin Invest 1993;91:2620-2629. (Pubitemid 23182517)
9. Romson JL, Hook BG, Kunkel SL, Abrams GD, Schork MA, Lucchesi BR. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation 1983;67:1016-1023. (Pubitemid 13080480)
10. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res 2008;58: 88-111.
11. Roberts R, DeMello V, Sobel BE. Deleterious effects of methylprednisolone in patients with myocardial infarction. Circulation 1976;53:I204-I206.
12. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107:3133-3140. (Pubitemid 36793081)
13. Timmers L, Sluijter JP, Verlaan CW, Steendijk P, Cramer MJ, Emons M et al. Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation 2007;115:326-332. (Pubitemid 46148507)
14. Tissieres A, Mitchell HK, Tracy UM. Protein synthesis in salivary glands of Drosophila melanogaster: Relation to chromosome puffs. J Mol Biol 1974;85:389-398.
15. Fan GC, Ren X, Qian J, Yuan Q, Nicolaou P, Wang Y et al. Novel cardioprotective role of a small heat-shock protein, Hsp20, against ischemia/reperfusion injury. Circulation 2005;111:1792-1799. (Pubitemid 40525144)
16. Martin JL, Mestril R, Hilal-Dandan R, Brunton LL, Dillmann WH. Small heat shock proteins and protection against ischemic injury in cardiac myocytes. Circulation 1997;96: 4343-4348. (Pubitemid 28007464)
17. Yellon DM, Iliodromitis E, Latchman DS, Van Winkle DM, Downey JM, Williams FM et al. Whole body heat stress fails to limit infarct size in the reperfused rabbit heart. Cardiovasc Res 1992;26:342-346.
18. Kim SC, Stice JP, Chen L, Jung JS, Gupta S, Wang Y et al. Extracellular heat shock protein 60, cardiac myocytes, and apoptosis. Circ Res 2009;105:1186-1195.
19. Li Y, Si R, Feng Y, Chen HH, Zou L, Wang E et al. Myocardial ischemia activates an injurious innate immune signaling via cardiac heat shock protein 60 and Toll-like receptor 4. J Biol Chem 2011;286:31308-31319.
20. Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004;5:825-830. (Pubitemid 39199174)
21. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A et al. Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004;279:7370-7377. (Pubitemid 38294612)
22. Ivanov S, Dragoi AM,Wang X, Dallacosta C, Louten J, Musco G et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 2007;110: 1970-1981. (Pubitemid 47443911)
23. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007;8:487-496. (Pubitemid 46605917)
24. Andrassy M, Volz HC, Igwe JC, Funke B, Eichberger SN, Kaya Z et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008;117: 3216-3226.
25. Kitahara T, Takeishi Y, Harada M, Niizeki T, Suzuki S, Sasaki T et al. High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice. Cardiovasc Res 2008;80:40-46.
26. Takahashi K, Fukushima S, Yamahara K, Yashiro K, Shintani Y, Coppen SR et al. Modulated inflammation by injection of high-mobility group box 1 recovers post-infarction chronically failing heart. Circulation 2008;118:S106-S114.
27. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005;11:1173-1179. (Pubitemid 43093664)
28. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T et al. Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002;195: 99-111. (Pubitemid 34074500)
29. Schoneveld AH, Hoefer I, Sluijter JP, Laman JD, de Kleijn DP, Pasterkamp G. Atherosclerotic lesion development and Toll-like receptor 2 and 4 responsiveness. Atherosclerosis 2008;197:95-104. (Pubitemid 351273277)
30. Arslan F, Smeets MB, Riem Vis PW, Karper JC, Quax PH, Bongartz LG et al. Lack of fibronectin-EDA promotes survival and prevents adverse remodeling and heart function deterioration after myocardial infarction. Circ Res 2011;108:582-592.
31. Arslan F, de Kleijn DP, Pasterkamp G. Innate immune signaling in cardiac ischemia. Nat Rev Cardiol 2011;8:292-300.
32. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388:394-397. (Pubitemid 27334820)
33. Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun 2009;388:621-625.
34. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499-511. (Pubitemid 38931765)
35. Schoneveld AH, Oude Nijhuis MM, van Middelaar B, Laman JD, de Kleijn DP, Pasterkamp G. Toll-like receptor 2 stimulation induces intimal hyperplasia and atherosclerotic lesion development. Cardiovasc Res 2005;66:162-169. (Pubitemid 40357879)
36. Vink A, Schoneveld AH, van der Meer JJ, van Middelaar BJ, Sluijter JP, Smeets MB et al. In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation 2002;106:1985-1990. (Pubitemid 35176306)
37. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009;54:2129-2138.
38. Boekholdt SM, Agema WR, Peters RJ, Zwinderman AH, van der Wall EE, Reitsma PH et al. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 2003;107:2416-2421. (Pubitemid 36605222)
39. Koch W, Hoppmann P, Pfeufer A, Schomig A, Kastrati A. Toll-like receptor 4 gene polymorphisms and myocardial infarction: no association in a Caucasian population. Eur Heart J 2006;27:2524-2529. (Pubitemid 44627294)
40. Fairweather D, Yusung S, Frisancho S, Barrett M, Gatewood S, Steele R et al. IL-12 receptor beta 1 and Toll-like receptor 4 increase IL-1 beta-and IL-18-associated myocarditis and coxsackievirus replication. J Immunol 2003;170:4731-4737. (Pubitemid 36519981)
41. Boyd JH, Mathur S,Wang Y, Bateman RM,Walley KR. Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. Cardiovasc Res 2006;72:384-393. (Pubitemid 44665856)
42. Knuefermann P, Schwederski M, Velten M, Krings P, Ehrentraut H, Rudiger M et al. Bacterial DNA induces myocardial inflammation and reduces cardiomyocyte contractility: role of toll-like receptor 9. Cardiovasc Res 2008;78:26-35. (Pubitemid 351430962)
43. Rowland RT, Meng X, Cleveland JC Jr., Meldrum DR, Harken AH, Brown JM. LPS-induced delayed myocardial adaptation enhances acute preconditioning to optimize postischemic cardiac function. Am J Physiol 1997;272:H2708-H2715.
44. Ha T, Hu Y, Liu L, Lu C, McMullen JR, Kelley J et al. TLR2 ligands induce cardioprotection against ischaemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Cardiovasc Res 2010;87:694-703.
45. Dong JW, Vallejo JG, Tzeng HP, Thomas JA, Mann DL. Innate immunity mediates myocardial preconditioning through Toll-like receptor 2 and TIRAP-dependent signaling pathways. Am J Physiol Heart Circ Physiol 2010;298:H1079-H1087.
46. Knuefermann P, Sakata Y, Baker JS, Huang CH, Sekiguchi K, Hardarson HS et al. Tolllike receptor 2 mediates Staphylococcus aureus-induced myocardial dysfunction and cytokine production in the heart. Circulation 2004;110:3693-3698. (Pubitemid 39665259)
47. Sakata Y, Dong JW, Vallejo JG, Huang CH, Baker JS, Tracey KJ et al. Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2007;292:H503-H509. (Pubitemid 46105213)
48. Oyama J, Blais C Jr, Liu X, Pu M, Kobzik L, Kelly RA et al. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 2004; 109:784-789. (Pubitemid 38222900)
49. Arslan F, Smeets MB, O'Neill LA, Keogh B, McGuirk P, Timmers L et al. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation 2010;121:80-90.
50. Feng Y, Zhao H, Xu X, Buys ES, Raher MJ, Bopassa JC et al. Innate immune adaptor MyD88 mediates neutrophil recruitment and myocardial injury after ischemia-reperfusion in mice. Am J Physiol Heart Circ Physiol 2008;295:H1311-H1318.
51. Shimamoto A, Chong AJ, Yada M, Shomura S, Takayama H, Fleisig AJ et al. Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation 2006;114:I270-I274. (Pubitemid 44297162)
52. Shishido T, Nozaki N, Yamaguchi S, Shibata Y, Nitobe J, Miyamoto T et al. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 2003;108:2905-2910. (Pubitemid 37517819)
53. Timmers L, Sluijter JP, van Keulen JK, Hoefer IE, Nederhoff MG, Goumans MJ et al. Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res 2008;102:257-264. (Pubitemid 351674064)
54. Timmers L, van Keulen JK, Hoefer IE, Meijs MF, van Middelaar B, den Ouden K et al. Targeted deletion of nuclear factor kappaB p50 enhances cardiac remodeling and dysfunction following myocardial infarction. Circ Res 2009;104:699-706.
55. Rossen RD, Michael LH, Hawkins HK, Youker K, Dreyer WJ, Baughn RE et al. Cardiolipin-protein complexes and initiation of complement activation after coronary artery occlusion. Circ Res 1994;75:546-555.
56. Krijnen PA, Ciurana C, Cramer T, Hazes T, Meijer CJ, Visser CA et al. IgM colocalises with complement and C reactive protein in infarcted human myocardium. J Clin Pathol 2005;58:382-388. (Pubitemid 40516169)
57. Nijmeijer R, Lagrand WK, Lubbers YT, Visser CA, Meijer CJ, Niessen HW et al. C-reactive protein activates complement in infarcted human myocardium. Am J Pathol 2003;163:269-275. (Pubitemid 36759611)
58. Ehrnthaller C, Ignatius A, Gebhard F, Huber-Lang M. New insights of an old defense system: structure, function, and clinical relevance of the complement system. Mol Med 2011;17:317-329.
59. Hill JH, Ward PA. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med 1971;133:885-900.
60. Jordan JE, Montalto MC, Stahl GL. Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation 2001;104:1413-1418. (Pubitemid 32880155)
61. Walsh MC, Bourcier T, Takahashi K, Shi L, Busche MN, Rother RP et al. Mannosebinding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol 2005;175:541-546. (Pubitemid 40884360)
62. Busche MN, Pavlov V, Takahashi K, Stahl GL. Myocardial ischemia and reperfusion injury is dependent on both IgM and mannose-binding lectin. Am J Physiol Heart Circ Physiol 2009;297:H1853-H1859.
63. Gorsuch WB, Guikema BJ, Fritzinger DC, Vogel CW, Stahl GL. Humanized cobra venom factor decreases myocardial ischemia-reperfusion injury. Mol Immunol 2009; 47:506-510.
64. Weisman HF, Bartow T, Leppo MK, Marsh HC Jr, Carson GR, Concino MF et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990;249:146-151.
65. Buerke M, Prufer D, Dahm M, Oelert H, Meyer J, Darius H. Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury. J Pharmacol Exp Ther 1998;286:429-438. (Pubitemid 28318019)
66. Amsterdam EA, Stahl GL, Pan HL, Rendig SV, Fletcher MP, Longhurst JC. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol 1995;268:H448-H457.
67. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998;97:2259-2267. (Pubitemid 28265388)
68. Zhang H, Qin G, Liang G, Li J, Barrington RA, Liu DX. C5aR-mediated myocardial ischemia/reperfusion injury. Biochem Biophys Res Commun 2007;357:446-452. (Pubitemid 46603152)
69. van der Pals J, Koul S, Andersson P, Gotberg M, Ubachs JF, Kanski M et al. Treatment with the C5a receptor antagonist ADC-1004 reduces myocardial infarction in a porcine ischemia-reperfusion model. BMC Cardiovasc Disord 2010;10:45.
70. Testa L, Van Gaal WJ, Bhindi R, Biondi-Zoccai GG, Abbate A, Agostoni P et al. Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients. J Thorac Cardiovasc Surg 2008;136:884-893.
71. de Zwaan C, Kleine AH, Diris JH, Glatz JF, Wellens HJ, Strengers PF et al. Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J 2002;23:1670-1677. (Pubitemid 36287778)
72. Fattouch K, Bianco G, Speziale G, Sampognaro R, Lavalle C, Guccione F et al. Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwent surgical reperfusion: a randomised double-blind study. Eur J Cardiothorac Surg 2007;32:326-332. (Pubitemid 47021452)
73. Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009;9:581-593.
74. Tushuizen ME, Diamant M, Sturk A, Nieuwland R. Cell-derived microparticles in the pathogenesis of cardiovascular disease: friend or foe? Arterioscler Thromb Vasc Biol 2011;31:4-9.
75. Obregon C, Rothen-Rutishauser B, Gitahi SK, Gehr P, Nicod LP. Exovesicles from human activated dendritic cells fuse with resting dendritic cells, allowing them to present alloantigens. Am J Pathol 2006;169:2127-2136. (Pubitemid 351181972)
76. Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988;263:18205-18212. (Pubitemid 19005097)
77. Szotowski B, Antoniak S, Goldin-Lang P, Tran QV, Pels K, Rosenthal P et al. Antioxidative treatment inhibits the release of thrombogenic tissue factor from irradiationand cytokine-induced endothelial cells. Cardiovasc Res 2007;73:806-812. (Pubitemid 46227358)
78. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 1999;99:348-353. (Pubitemid 29051259)
79. Barry OP, Pratico D, Savani RC, FitzGerald GA. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest 1998;102:136-144. (Pubitemid 28323840)
80. Huber J, Vales A, Mitulovic G, Blumer M, Schmid R, Witztum JL et al. Oxidized membrane vesicles and blebs from apoptotic cells contain biologically active oxidized phospholipids that induce monocyte-endothelial interactions. Arterioscler Thromb Vasc Biol 2002;22:101-107. (Pubitemid 34076239)
81. Mesri M, Altieri DC. Endothelial cell activation by leukocyte microparticles. J Immunol 1998;161:4382-4387. (Pubitemid 28469024)
82. Bhatnagar S, Shinagawa K, Castellino FJ, Schorey JS. Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo. Blood 2007;110:3234-3244. (Pubitemid 350106316)
83. Azevedo LC, Janiszewski M, Pontieri V, Pedro Mde A, Bassi E, Tucci PJ et al. Plateletderived exosomes from septic shock patients induce myocardial dysfunction. Crit Care 2007;11:R120.
84. Boilard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, Weinblatt ME et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 2010;327:580-583.
85. Koppler B, Cohen C, Schlondorff D, Mack M. Differential mechanisms of microparticle transfer to B cells and monocytes: anti-inflammatory properties of microparticles. Eur J Immunol 2006;36:648-660.
86. Peterson DB, Sander T, Kaul S, Wakim BT, Halligan B, Twigger S et al. Comparative proteomic analysis of PAI-1 and TNF-alpha-derived endothelial microparticles. Proteomics 2008;8:2430-2446.
87. Timmers L, Lim SK, Arslan F, Armstrong JS, Hoefer IE, Doevendans PA et al. Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res 2007;1:129-137.
88. Timmers L, Lim SK, Hoefer IE, Arslan F, Lai RC, van Oorschot AA et al. Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. Stem Cell Res 2011;6:206-214.
89. Lai RC, Arslan F, Lee MM, Sze NS, Choo A, Chen TS et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res 2010;4:214-222.
90. Hagiwara S, Iwasaka H, Shingu C, Matumoto S, Hasegawa A, Noguchi T. Heat shock protein 47 (HSP47) antisense oligonucleotides reduce cardiac remodeling and improve cardiac function in a rat model of myocardial infarction. Thorac Cardiovasc Surg 2011;59:386-392.
91. Efthymiou CA, Mocanu MM, de Belleroche J, Wells DJ, Latchmann DS, Yellon DM. Heat shock protein 27 protects the heart against myocardial infarction. Basic Res Cardiol 2004;99:392-394. (Pubitemid 39462361)
92. Qian J, Ren X, Wang X, Zhang P, Jones WK, Molkentin JD et al. Blockade of Hsp20 phosphorylation exacerbates cardiac ischemia/reperfusion injury by suppressed autophagy and increased cell death. Circ Res 2009;105:1223-1231.
93. Hamid T, Guo SZ, Kingery JR, Xiang X, Dawn B, Prabhu SD. Cardiomyocyte NF-kappaB p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. Cardiovasc Res 2011;89:129-138.
94. Frantz S, Hu K, Bayer B, Gerondakis S, Strotmann J, Adamek A et al. Absence of NF-kappaB subunit p50 improves heart failure after myocardial infarction. FASEB J 2006;20:1918-1920.
95. Moss NC, Stansfield WE, Willis MS, Tang RH, Selzman CH. IKKbeta inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2007;293:H2248-H2253. (Pubitemid 47605868)